Pregnancy Outcomes Following in Utero Exposure to Second-Generation Antipsychotics: A Systematic Review and Meta-Analysis

Journal of Clinical Psychopharmacology

Volumn 35, Issue 5, 2015, Pages 559-565

  Terrana, Nathan ^a   Koren, Gideon ^a,b   Pivovarov, Jacklyn ^a   Etwel, Fatma ^b   Nulman, Irena ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

major congenital malformations; pregnancy; pregnancy outcomes; psychiatric disorders; second generation antipsychotics; teratogen

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

BIRTH WEIGHT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONGENITAL MALFORMATION; CORRELATION ANALYSIS; DRUG SAFETY; EMBASE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; LARGE FOR GESTATIONAL AGE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMALL FOR DATE INFANT; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; ABNORMALITIES, DRUG-INDUCED; FEMALE; MENTAL DISORDERS; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; RISK;

ABNORMALITIES, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; INFANT, NEWBORN; MENTAL DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH; RISK;

EID: 84941272535     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000391     Document Type: Review

References (47)

1. SundströmIM, Bixo M, Björn I, et al. Prevalence of psychiatric disorders in gynecologic outpatients. Am J Obstet Gynecol. 2001;184:8-13.
2. Nicholson J, Biebel K, Williams VF, et al. Prevalence of parenthood in adults with mental illness: implications for state and federal policy, programs, and providers. In: Manderscheid RW, HendersonMJ; Center for Mental Health Services. Mental Health, United States, 2002. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004; 120-137.
3. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medication in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20:177-184.
4. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010;36:518-544.
5. Howard LM, Goss C, Leese M, et al. The psychosocial outcome of pregnancy with psychotic disorders. Schizophr Res. 2004;71:49-90.
6. Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164:1214-1220.
7. Atypical Antipsychotics Drugs Information. U.S. Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm094303. htm. Updated June 18, 2013. Accessed February 9, 2014.
8. Habermann F, Fritzsche J, Fuhlbrück F, et al. Atypical antipsychotic drugs and pregnancy outcome. J Clin Psychopharmacol. 2013;33:453-462.
9. Paulus W, Schloemp S, Sterzik K, et al. Atypical antipsychotic agents in early pregnancy. Reprod Toxicol. 2005;20:477.
10. Sadowski A, Todorow M, Yazdani Brojeni P, et al. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open. 2013;3:e003062.
11. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66:444-449.
12. Bellet F, Beyens MN, Bernard N, et al. Pregnancy outcome in women exposed to aripiprazole during the embryonic period: a prospective multicentric cohort. Fundam Clin Pharmacol. 2013;27:43.
13. Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28:279-288.
14. Vial T, Merieux C, Garayt C, et al. Pregnancy outcome in women exposed to atypical antipsychotics. Drug Saf. 2009;32:933-934.
15. Paulus WE. Is the use of aripiprazole safe during first trimester of pregnancy? ENTIS Meeting Abstracts April 20-22, 2013. Reprod Toxicol. 2013;37:87.
16. Bodén R, Lundgren M, Brandt L, et al. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012; 69:715-721.
17. Lin H, Chen I, Chen Y, et al. Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res. 2010;116:55-60.
18. Newham JJ, Thomas SH, MacRitchie K, et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008;192:333-337.
19. Wells GA, Shea B, O'Connor D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa, Canada: Department of Epidemiology and Community Medicine, University of Ottawa. Ottawa Hospital Research Institute Web site. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford. htm. Accessed August 2013.
20. Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Reprint-preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther. 2009;89:873-880.
21. BorensteinM. Introduction to Meta-analysis. Chichester, United Kingdom: John Wiley & Sons; 2009:25.
22. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
23. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-463.
24. Hironaka M, Kotani T, Sumigama S, et al. Maternal mental disorders and pregnancy outcomes: a clinical study in a Japanese population. J Obstet Gynaecol Res. 2011;37:1283-1289.
25. Herbison P, Hay-Smith J, Gillespie WJ. Meta-analyses of small numbers of trials often agree with longer-term results. J Clin Epidemiol. 2011;64:145-153.
26. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol. 2000;20:399-403.
27. Twaites BR, Wilton LV, Shakir SA. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England. J Psychopharmacol. 2007;21:392-399.
28. Coppola D, Russo LJ, Kwarta RF, et al. Evaluating the postmarketing experience of risperidone use during pregnancy. Drug Saf. 2007;30: 247-264.
29. Brunner E, Falk DM, Jones M, et al. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol. 2013;14:38.
30. Hoffman JIL, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890-1900.
31. Koren G. The effect of ascertainment bias in evaluating gestational antidepressant exposure. J Popul Ther Clin Pharmacol. 2011;18: e174-e175.
32. Jablensky AV, Morgan V, Zubrick SR, et al. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry. 2005;162: 79-91.
33. Hizkiyahu R, Levy A, Sheiner E. Pregnancy outcome of patients with schizophrenia. Am J Perinatol. 2010;27:19-23.
34. Gentile S. Long term atypical antipsychotics treatment and risk of weight gain. A literature analysis. Drug Saf. 2006;29:303-319.
35. Waller DK, ShawGM, Rasmussen AS, et al. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med. 2007;161: 745-750.
36. Rush RW, Keirse MJ, Howat P, et al. Contribution of preterm delivery to perinatal mortality. Br Med J. 1976;2:965-968.
37. Scheuchenegger A, Lechner E, Wiesinger-Eidenberger G, et al. Short-term morbidities of moderate and late preterm infants. Klin Padiatr. 2014;226: 216-220.
38. Russell RB, Green NS, Steiner CA, et al. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics. 2007;120:e1-e9.
39. Bain M, Juszczak E, McInney K, et al. Obstetric complications and affective psychosis. Two case-control studies based on structured obstetric records. Br J Psychiatry. 2000;176:523-526.
40. Khatibi A, Brantsaeter AL, Sengpiel V, et al. Prepregnancy maternal body mass index and preterm delivery. Am J Obstet Gynecol. 2012;207:e1-e7.
41. Nilsson E, Lichtenstein P, Cnattingius S, et al.Women with schizophrenia: pregnancy outcome and infant death among their offspring. Schizophr Res. 2002;58:221-229.
42. Davalos D, Yadon C, Tregellas H. Untreated prenatal maternal depression and potential risks to offspring: a review. Arch Womens Ment Health. 2012; 15:1-14.
43. Lee HC, Lin HC.Maternal bipolar disorder increased low birth weight and preterm births: a nationwide population-based study. J Affect Disord. 2012; 121:100-105.
44. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6:1221-1286.
45. Nielsen GL, DethlefsenC, Mollert M, et al.Maternal glycated hemoglobin, pre-gestational weight, pregnancy weight and risk of large-for-gestational-age neonates: a Danish cohort study of 209 singleton Type 1 diabetic pregnancies. Diabet Med. 2007;24:384-387.
46. Slone D, Siskind V, Heinonen OP, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol. 1977;128:486-488.
47. Diav-Citrin O, Shechtman S, Ornoy S, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry. 2005;66:317-322.